Importantly, our molecular mechanism exploration in this study revealed that inhibition of HDAC2 promoted the expression of miR-130a-3p, thereby inhibiting Rad51, which ultimately reduced the resistance of mut-KRAS NSCLC to Pem. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.